Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have received an average rating of “Hold” from the twelve research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $18.13.
IRWD has been the topic of several analyst reports. Mizuho restated a “buy” rating and issued a $22.00 target price on shares of Ironwood Pharmaceuticals in a research report on Sunday, July 23rd. BidaskClub upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Wells Fargo & Company set a $19.00 target price on Ironwood Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, July 22nd. Cowen and Company set a $20.00 price target on Ironwood Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 4th. Finally, Zacks Investment Research raised Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 17th.
ILLEGAL ACTIVITY NOTICE: “Ironwood Pharmaceuticals, Inc. (IRWD) Given Average Recommendation of “Hold” by Brokerages” was originally published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.themarketsdaily.com/2017/09/12/ironwood-pharmaceuticals-inc-irwd-given-average-recommendation-of-hold-by-brokerages.html.
In other Ironwood Pharmaceuticals news, insider Halley E. Gilbert sold 35,000 shares of the stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $19.75, for a total transaction of $691,250.00. Following the completion of the transaction, the insider now directly owns 35,000 shares of the company’s stock, valued at approximately $691,250. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 36,707 shares of company stock valued at $718,458. 7.63% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Ironwood Pharmaceuticals by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 10,761,867 shares of the biotechnology company’s stock worth $203,184,000 after acquiring an additional 256,406 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of Ironwood Pharmaceuticals during the 2nd quarter worth $150,460,000. Brown Capital Management LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter worth $86,854,000. State Street Corp boosted its stake in shares of Ironwood Pharmaceuticals by 13.7% during the 2nd quarter. State Street Corp now owns 4,530,267 shares of the biotechnology company’s stock worth $85,533,000 after acquiring an additional 545,464 shares in the last quarter. Finally, EcoR1 Capital LLC boosted its stake in shares of Ironwood Pharmaceuticals by 29.2% during the 2nd quarter. EcoR1 Capital LLC now owns 3,753,635 shares of the biotechnology company’s stock worth $70,869,000 after acquiring an additional 848,120 shares in the last quarter. 97.95% of the stock is owned by institutional investors and hedge funds.
Ironwood Pharmaceuticals (NASDAQ IRWD) opened at 15.36 on Tuesday. The stock has a 50 day moving average price of $15.76 and a 200-day moving average price of $17.10. Ironwood Pharmaceuticals has a 12-month low of $12.48 and a 12-month high of $19.94. The firm’s market cap is $2.30 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.05. Ironwood Pharmaceuticals had a negative net margin of 52.97% and a negative return on equity of 333.83%. The business had revenue of $65.10 million during the quarter, compared to analyst estimates of $70 million. During the same quarter in the prior year, the business earned ($0.16) earnings per share. The firm’s revenue was up 19.7% compared to the same quarter last year. Equities analysts forecast that Ironwood Pharmaceuticals will post ($1.10) earnings per share for the current year.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.